Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors
Goel, Sanjay, Viteri, Santiago, Morán, Teresa, Coronado, Cinthya, Dios, Jorge Luis Iglesias, Miguel-Lillo, Bernardo, Fernández-García, Eva M., Rosell, Rafael
Published in Investigational new drugs (01.02.2016)
Published in Investigational new drugs (01.02.2016)
Get full text
Journal Article
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study
Moreno, Irene, Hernández, Tatiana, Calvo, Emiliano, Fudio, Salvador, Kahatt, Carmen, Martínez, Sara, Iglesias, Jorge Luis, Calafati, Román Octavio, Pérez-Ramos, Laura, Montilla, Lola, Zeaiter, Ali, Lubomirov, Rubin
Published in Marine drugs (01.04.2024)
Published in Marine drugs (01.04.2024)
Get full text
Journal Article
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study
Moreno, Irene, Hernández, Tatiana, Calvo, Emiliano, Fudio, Salvador, Kahatt, Carmen, Fernández, Cristian, Iglesias, Jorge Luis, Corral, Gema, Pérez-Ramos, Laura, Montilla, Lola, Zeaiter, Ali, Lubomirov, Rubin
Published in Pharmaceuticals (Basel, Switzerland) (30.01.2024)
Published in Pharmaceuticals (Basel, Switzerland) (30.01.2024)
Get full text
Journal Article
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies
Goldwasser, Francois, Faivre, Sandrine, Alexandre, Jerome, Coronado, Cinthya, Fernández-García, Eva M., Kahatt, Carmen M., Paramio, Pilar García, Dios, Jorge Luis Iglesias, Miguel-Lillo, Bernardo, Raymond, Eric
Published in Investigational new drugs (01.06.2014)
Published in Investigational new drugs (01.06.2014)
Get full text
Journal Article
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule
Jimeno, Antonio, Sharma, Manish R., Szyldergemajn, Sergio, Gore, Lia, Geary, David, Diamond, Jennifer R., Fernandez Teruel, Carlos, Soto Matos-Pita, Arturo, Iglesias, Jorge Luis, Cullell-Young, Martin, Ratain, Mark J.
Published in Investigational new drugs (01.08.2017)
Published in Investigational new drugs (01.08.2017)
Get full text
Journal Article
Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial)
Petty, Russell, Anthoney, Alan, Metges, Jean-Philippe, Alsina, Maria, Gonçalves, Anthony, Brown, Jennifer, Montagut, Clara, Gunzer, Katharina, Laus, Gianluca, Iglesias Dios, Jorge Luis, Miguel-Lillo, Bernardo, Bohan, Patrick, Salazar, Ramón
Published in Cancer chemotherapy and pharmacology (01.04.2016)
Published in Cancer chemotherapy and pharmacology (01.04.2016)
Get full text
Journal Article
Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors
Goel, Sanjay, Moran, Teresa, Coronado, Cinthya, Viteri Ramirez, Santiago, Chaudhary, Imran, Ghalib, Mohammad Haroon, Swami, Umang, Hou, Yijuan, Carcereny, Enric, Alcantara, Jose, Iglesias Dios, Jorge Luis, De Miguel, Bernardo, Buges, Cristina, Rosell, Rafael
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article